Morgan Stanley has trimmed SINOPHARM's (01099) profit projections for 2025-2030 by 1%-6%, citing reduced sales forecasts within its medical apparatus and pharmaceutical distribution divisions. Consequently, the investment bank adjusted its price target downward from HK$23 to HK$22.5 while maintaining an "Overweight" rating on the stock.
The revised outlook reflects anticipated headwinds in two core business segments, though analysts continue to endorse strategic positioning for long-term growth potential. This recalibration aligns with evolving market dynamics in China's healthcare distribution landscape, where SINOPHARM maintains significant market presence.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.